4D Molecular Therapeutics receives FDA clearance for GAZE Phase 1 trial of 4D-175, a genetic medicine for age-related macular degeneration.
4D Molecular Therapeutics (4DMT) received FDA clearance for its IND application of 4D-175, a genetic medicine for treating geographic atrophy (GA) in age-related macular degeneration patients. The Phase 1 GAZE clinical trial will start enrollment in H2 2024, exploring safety, tolerability, and doses. The single-injection treatment aims to reduce treatment burden and potentially improve long-term vision outcomes.
June 24, 2024
3 Articles